Get access

Inhalational and topical steroids, and oral candidosis: a mini review

Authors

  • ANB Ellepola,

    1. Oral Bio-sciences, Faculty of Dentistry, University of Hong Kong, Hong Kong SAR;
    2. Division of Pharmacology, Department of Oral Medicine, Faculty of Dental Sciences, University of Peradeniya, Sri Lanka
    Search for more papers by this author
  • LP Samaranayake

    1. Oral Bio-sciences, Faculty of Dentistry, University of Hong Kong, Hong Kong SAR;
    Search for more papers by this author

Professor LP Samaranayake, Oral Bio-sciences, Faculty of Dentistry, The Prince Philip Dental Hospital, 34 Hospital Road, Hong Kong. Tel: 852 2859 0480, Fax: 852 2547 6133 E-mail: lakshman@hkucc.hku.hk

Abstract

Candidosis is by far the commonest oral fungal infection in man and could manifest as an adverse effect of drug therapy such as inhaled or topically applied corticosteroids. Due to the anti-inflammatory and immunosuppressive effect steroids are used in the management of bronchial asthma and oral mucosal diseases. In this mini review we discuss the clinical and laboratory findings on the relationship between steroid inhalers, other topical steroids and oral candidosis, possible mechanisms of pathogenicity following such therapy as well as the precautions that could be taken to minimize this adverse side effect.

Get access to the full text of this article

Ancillary